Skip to main content

Advertisement

SpringerLink
Log in

Erythropoetin as a novel agent with pleiotropic effects against acute lung injury

  • Review Article
  • Published:
European Journal of Clinical Pharmacology Aims and scope Submit manuscript

Abstract

Current pharmacotherapy for acute lung injury (ALI) and acute respiratory distress syndrome (ARDS) is not optimal, and the biological and physiological complexity of these severe lung injury syndromes requires consideration of combined-agent treatments or agents with pleiotropic action. In this regard, exogenous erythropoietin (EPO) represents a possible candidate since a number of preclinical studies have revealed beneficial effects of EPO administration in various experimental models of ALI. Taken together, this treatment strategy is not a single mediator approach, but it rather provides protection by modulating multiple levels of early signaling pathways involved in apoptosis, inflammation, and peroxidation, potentially restoring overall homeostasis. Furthermore, EPO appears to confer vascular protection by promoting angiogenesis. However, only preliminary studies exist and more experimental and clinical studies are necessary to clarify the efficacy and potentially cytoprotective mechanisms of EPO action. In addition to the attempts to optimize the dose and timing of EPO administration, it would be of great value to minimize any potential toxicity, which is essential for EPO to fulfill its role as a potential candidate for the treatment of ALI in routine clinical practice. The present article reviews recent advances that have elucidated biological and biochemical activities of EPO that may be potentially applicable for ALI/ARDS management.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Bernard GR, Artigas A, Brigham KL, Carlet J, Falke K, Hudson L, Lamy M, Legall JR, Morris A, Spragg R (1994) The American–European Consensus Conference on ARDS. Definitions, mechanisms, relevant outcomes, and clinical trial coordination. Am J Respir Crit Care Med 149:818–824

    CAS  PubMed  Google Scholar 

  2. Matthay MA, Zimmerman GA (2005) Acute lung injury and the acute respiratory distress syndrome: four decades of inquiry into pathogenesis and rational management. Am J Respir Cell Mol Biol 33:319–327

    Article  CAS  PubMed  Google Scholar 

  3. Wheeler AP, Bernard GR (2007) Acute lung injury and the acute respiratory distress syndrome: a clinical review. Lancet 369:1553–1564

    Article  PubMed  Google Scholar 

  4. Baue AE, Durham R, Faist E (1998) Systemic inflammatory response syndrome (SIRS), multiple organ dysfunction syndrome (MODS), multiple organ failure (MOF): are we winning the battle? Shock 10:79–89

    Article  CAS  PubMed  Google Scholar 

  5. Boueiz A, Hassoun PM (2009) Regulation of endothelial barrier function by reactive oxygen and nitrogen species. Microvasc Res 77(1):26–34

    Article  CAS  PubMed  Google Scholar 

  6. Crimi E, Slutsky AS (2004) Inflammation and the acute respiratory distress syndrome. Best Pract Res Clin Anaesthesiol 18:477–492

    Article  CAS  PubMed  Google Scholar 

  7. Perl M, Lomas-Neira J, Chung CS, Ayala A (2008) Epithelial cell apoptosis and neutrophil recruitment in acute lung injury–a unifying hypothesis? What we have learned from small interfering RNAs. Mol Med 14:465–475

    Article  CAS  PubMed  Google Scholar 

  8. Tang PS, Mura M, Seth R, Liu M (2008) Acute lung injury and cell death: how many ways can cells die? Am J Physiol Lung Cell Mol Physiol 294:L632–641

    Article  CAS  PubMed  Google Scholar 

  9. Tasaka S, Amaya F, Hashimoto S, Ishizaka A (2008) Roles of oxidants and redox signaling in the pathogenesis of acute respiratory distress syndrome. Antioxid Redox Signal 10:739–753

    Article  CAS  PubMed  Google Scholar 

  10. Vincent JL, Zambon M (2006) Why do patients who have acute lung injury/acute respiratory distress syndrome die from multiple organ dysfunction syndrome? Implications for management. Clin Chest Med 27:725–731

    Article  PubMed  Google Scholar 

  11. Brun-Buisson C, Minelli C, Bertolini G, Brazzi L, Pimentel J, Lewandowski K, Bion J, Romand JA, Villar J, Thorsteinsson A, Damas P, Armaganidis A, Lemaire F, ALIVE Study Group (2004) Epidemiology and outcome of acute lung injury in European intensive care units. Results from the ALIVE study. Intensive Care Med 30:51–61

    Article  PubMed  Google Scholar 

  12. Rubenfeld GD, Caldwell E, Peabody E, Weaver J, Martin DP, Neff M, Stern EJ, Hudson LD (2005) Incidence and outcomes of acute lung injury. N Engl J Med 353:1685–1693

    Article  CAS  PubMed  Google Scholar 

  13. The Acute Respiratory Distress Syndrome Network (2000) Ventilation with lower tidal volumes as compared with traditional tidal volumes for acute lung injury and the acute respiratory distress syndrome. N Engl J Med 342:1301–1308

    Article  Google Scholar 

  14. Hopkins RO, Herridge MS (2006) Quality of life, emotional abnormalities, and cognitive dysfunction in survivors of acute lung injury/acute respiratory distress syndrome. Clin Chest Med 27:679–689

    Article  PubMed  Google Scholar 

  15. McHugh LG, Milberg JA, Whitcomb ME, Schoene RB, Maunder RJ, Hudson LD (1994) Recovery of function in survivors of the acute respiratory distress syndrome. Am J Respir Crit Care Med 150:90–94

    CAS  PubMed  Google Scholar 

  16. Raghavendran K, Pryhuber GS, Chess PR, Davidson BA, Knight PR, Notter RH (2008) Pharmacotherapy of acute lung injury and acute respiratory distress syndrome. Curr Med Chem 15:1911–1924

    Article  CAS  PubMed  Google Scholar 

  17. Coleman T, Brines M (2004) Science review: recombinant human erythropoietin in critical illness: a role beyond anemia? Crit Care 8:337–341

    Article  PubMed  Google Scholar 

  18. Maiese K, Chong ZZ, Shang YC (2008) Raves and risks for erythropoietin. Cytokine Growth Factor Rev 19:145–155

    Article  CAS  PubMed  Google Scholar 

  19. Thiemermann C (2007) Beneficial effects of erythropoietin in preclinical models of shock and organ failure. Crit Care 11:132

    Article  PubMed  Google Scholar 

  20. Jelkmann W, Hellwig-Burgel T (2001) Biology of erythropoietin. Adv Exp Med Biol 502:169–187

    CAS  PubMed  Google Scholar 

  21. Farrell F, Lee A (2004) The erythropoietin receptor and its expression in tumor cells and other tissues. Oncologists 9:18–30

    Article  CAS  Google Scholar 

  22. Lacombe C, Da Silva JL, Bruneval P, Casadevall N, Camilleri JP, Bariety J, Tambourin P, Varet B (1991) Erythropoietin: sites of synthesis and regulation of secretion. Am J Kidney Dis S1:14–19

    Google Scholar 

  23. Brines M, Grasso G, Fiordaliso F, Sfacteria A, Ghezzi P, Fratelli M, Latini R, Xie QW, Smart J, Su-Rick CJ, Pobre E, Diaz D, Gomez D, Hand C, Coleman T, Cerami A (2004) Erythropoietin mediates tissue protection through an erythropoietin and common beta–subunit heteroreceptor. Proc Natl Acad Sci USA 101:14907–14912

    Article  CAS  PubMed  Google Scholar 

  24. Rogiers P, Zhang H, Leeman M, Nagler J, Neels H, Mélot C, Vincent JL (1997) Erythropoietin response is blunted in critically ill patients. Intensive Care Med 23:159–162

    Article  CAS  PubMed  Google Scholar 

  25. Faquin WC, Schneider TJ, Goldberg MA (1992) Effect of inflammatory cytokines on hypoxia-induced erythropoietin production. Blood 79:1987–1994

    CAS  PubMed  Google Scholar 

  26. Abel J, Spannbrucker N, Fandrey J, Jelkmann W (1996) Serum erythropoietin levels in patients with sepsis and septic shock. Eur J Haematol 57:359–363

    Article  CAS  PubMed  Google Scholar 

  27. Tamion F, Le Cam-Duchez V, Menard JF, Girault C, Coquerel A, Bonmarchand G (2004) Erythropoietin and renin as biological markers in critically ill patients. Crit Care 8:R328–335

    Article  PubMed  Google Scholar 

  28. Ehrenreich H, Hasselblatt M, Dembowski C, Cepek L, Lewczuk P, Stiefel M, Rustenbeck HH, Breiter N, Jacob S, Knerlich F, Bohn M, Poser W, Rüther E, Kochen M, Gefeller O, Gleiter C, Wessel TC, De Ryck M, Itri L, Prange H, Cerami A, Brines M, Sirén AL (2002) Erythropoietin therapy for acute stroke is both safe and beneficial. Mol Med 8:495–505

    CAS  PubMed  Google Scholar 

  29. Lipsic E, van der Meer P, Voors AA, Westenbrink BD, van den Heuvel AF, de Boer HC, van Zonneveld AJ, Schoemaker RG, van Gilst WH, Zijlstra F, van Veldhuisen DJ (2006) A single bolus of a long-acting erythropoietin analogue darbepoetin alfa in patients with acute myocardial infarction: a randomized feasibility and safety study. Cardiovasc Drugs Ther 20:135–141

    Article  CAS  PubMed  Google Scholar 

  30. Lee JH, Sung DK, Koo SH, Shin BK, Hong YS, Son CS, Lee JW, Chang YS, Park WS (2007) Erythropoietin attenuates hyperoxia-induced lung injury by down-modulating inflammation in neonatal rats. J Korean Med Sci 22:1042–1047

    Article  CAS  PubMed  Google Scholar 

  31. Ozer EA, Kumral A, Ozer E, Yilmaz O, Duman N, Ozkal S, Koroglu T, Ozkan H (2005) Effects of erythropoietin on hyperoxic lung injury in neonatal rats. Pediatr Res 58:38–41

    Article  CAS  PubMed  Google Scholar 

  32. Tascilar O, Cakmak GK, Tekin IO, Emre AU, Ucan BH, Bahadir B, Acikgoz S, Irkorucu O, Karakaya K, Balbaloglu H, Kertis G, Ankarali H, Comert M (2007) Protective effects of erythropoietin against acute lung injury in a rat model of acute necrotizing pancreatitis. World J Gastroenterol 13:6172–6182

    Article  CAS  PubMed  Google Scholar 

  33. Wu H, Ren B, Zhu J, Dong G, Xu B, Wang C, Zheng X, Jing H (2006) Pretreatment with recombined human erythropoietin attenuates ischemia-reperfusion-induced lung injury in rats. Eur J Cardiothorac Surg 29:902–907

    Article  PubMed  Google Scholar 

  34. Wu H, Dong G, Liu H, Xu B, Li D, Jing H (2009) Erythropoietin attenuates ischemia-reperfusion induced lung injury by inhibiting tumor necrosis factor-alpha and matrix metalloproteinase-9 expression. Eur J Pharmacol 602:406–412

    Article  CAS  PubMed  Google Scholar 

  35. Aoshiba K, Onizawa S, Tsuji T, Nagai A (2009) Τherapeutic effects of erythropoietin in murine models of endotoxin shock. Crit Care Med 37:889–898

    Article  CAS  PubMed  Google Scholar 

  36. Shang Y, Li X, Prasad PV, Xu S, Yao S, Liu D, Yuan S, Feng D (2009) Erythropoietin attenuates lung injury in lipopolysaccharide treated rats. J Surg Res 155:104–110

    Article  CAS  PubMed  Google Scholar 

  37. Shang Y, Jiang YX, Xu SP, Wu Y, Wu ZY, Yuan SY, Yao SL (2009) Reduction of pulmonary inflammatory response by erythropoietin in a rat model of endotoxaemia. Chin Med J Engl 122:834–838

    CAS  PubMed  Google Scholar 

  38. Cuzzocrea S, Di Paola R, Mazzon E, Patel NS, Genovese T, Muia C, Crisafulli C, Caputi AP, Thiemermann C (2006) Erythropoietin reduces the development of nonseptic shock induced by zymosan in mice. Crit Care Med 34:1168–1177

    Article  CAS  PubMed  Google Scholar 

  39. Yildirim E, Ozisik K, Solaroglu I, Kaptanoglu E, Beskonakli E, Sargon MF, Kilinc K, Sakinci U (2005) Protective effect of erythropoietin on type II pneumocyte cells after traumatic brain injury in rats. J Trauma 58:1252–1258

    Article  CAS  PubMed  Google Scholar 

  40. Carlini RG, Alonzo EJ, Dominguez J, Blanca I, Weisinger JR, Rothstein M, Bellorin-Font E (1999) Effect of recombinant human erythropoietin on endothelial cell apoptosis. Kidney Int 55:546–553

    Article  CAS  PubMed  Google Scholar 

  41. Yoshimi M, Maeyama T, Yamada M, Hamada N, Fukumoto J, Kawaguchi T, Kuwano K, Nakanishi Y (2008) Recombinant human erythropoietin reduces epithelial cell apoptosis and attenuates bleomycin-induced pneumonitis in mice. Respirology 13:639–645

    Article  PubMed  Google Scholar 

  42. MacRedmond R, Singhera GK, Dorscheid DR (2009) Erythropoietin inhibits respiratory epithelial cell apoptosis in a model of acute lung injury. Eur Respir J 33:1403–1414

    Article  CAS  PubMed  Google Scholar 

  43. di Villa Bianca RE, Sorrentino R, Mitidieri E, Marzocco S, Autore G, Thiemermann C, Pinto A, Sorrentino R (2009) Recombinant human erythropoietin prevents lipopolysaccharide-induced vascular hyporeactivity in the rat. Shock 31:529–534

    Article  PubMed  Google Scholar 

  44. Ding L, Wu BQ, Huang JJ, Liu ZP, Chen L (2010) Effect of erythropoietin on apoptosis following hyperoxic lung injury in neonatal rats. Zhongguo Dang Dai Er Ke Za Zhi 12:576–9

    CAS  PubMed  Google Scholar 

  45. Kertesz N, Wu J, Chen TH, Sucov HM, Wu H (2004) The role of erythropoietin in regulating angiogenesis. Dev Biol 276:101–110

    Article  CAS  PubMed  Google Scholar 

  46. Ribatti D, Presta M, Vacca A, Ria R, Giuliani R, Dell'Era P, Nico B, Roncali L, Dammacco F (1999) Human erythropoietin induces a pro-angiogenic phenotype in cultured endothelial cells and stimulates neovascularization in vivo. Blood 93:2627–2636

    CAS  PubMed  Google Scholar 

  47. van der Meer P, Lipsic E, Henning RH, Boddeus K, van der Velden J, Voors AA, van Veldhuisen DJ, van Gilst WH, Schoemaker RG (2005) Erythropoietin induces neovascularization and improves cardiac function in rats with heart failure after myocardial infarction. J Am Coll Cardiol 46:125–133

    Article  PubMed  Google Scholar 

  48. Victoria M, Arroyo A, Castilla MA, Pacheco FRG, Tan D, Riesco A, Casado S, Caramelo C (1998) Role of vascular endothelial growth factor on erythropoietin-related endothelial cell proliferation. J Am Soc Nephrol 9:1998–2004

    Google Scholar 

  49. Lahm T, Crisostomo PR, Markel TA, Wang M, Lillemoe KD, Meldrum DR (2007) The critical role of vascular endothelial growth factor in pulmonary vascular remodeling after lung injury. Shock 28:4–14

    Article  CAS  PubMed  Google Scholar 

  50. Keogh CL, Yu SP, Wei LJ (2007) The effect of recombinant human erythropoietin on neurovasculature repair after focal ischemic stroke in neonatal rats. Pharmacol Exp Ther 322:521–528

    Article  CAS  Google Scholar 

  51. Yancopoulos GD, Davis S, Gale NW, Rudge JS, Wiegand SJ, Holash J (2000) Vascular-specific growth factors and blood vessel formation. Nature 407:242–248

    Article  CAS  PubMed  Google Scholar 

  52. Karmpaliotis D, Kosmidou I, Ingenito EP, Hong K, Malhotra A, Sunday ME, Haley KJ (2002) Angiogenic growth factors in the pathophysiology of a murine model of acute lung injury. Am J Physiol Lung Cell Mol Physiol 283:L585–595

    CAS  PubMed  Google Scholar 

  53. McCarter SD, Mei SH, Lai PF, Zhang QW, Parker CH, Suen RS, Hood RD, Zhao YD, Deng Y, Han RN, Dumont DJ, Stewart DJ (2007) Cell-based angiopoietin-1 gene therapy for acute lung injury. Am J Respir Crit Care Med 175:1014–1026

    Article  CAS  PubMed  Google Scholar 

  54. Heeschen C, Aicher A, Lehmann R, Fichtlscherer S, Vasa M, Urbich C, Mildner-Rihm C, Martin H, Zeiher AM, Dimmeler S (2003) Erythropoietin is a potent physiologic stimulus for endothelial progenitor cell mobilization. Blood 102:1340–1346

    Article  CAS  PubMed  Google Scholar 

  55. Satoh K, Kagaya Y, Nakano M, Ito Y, Ohta J, Tada H, Karibe A, Minegishi N, Suzuki N, Yamamoto M, Ono M, Watanabe J, Shirato K, Ishii N, Sugamura K, Shimokawa H (2006) Important role of endogenous erythropoietin system in recruitment of endothelial progenitor cells in hypoxia-induced pulmonary hypertension in mice. Circulation 113(11):1442–50

    Article  CAS  PubMed  Google Scholar 

  56. Juul SE (2000) Nonerythropoietic roles of erythropoietin in the fetus and neonate. Clin Perinatol 27:527–541

    Article  CAS  PubMed  Google Scholar 

  57. Nagaya N, Kangawa K, Kanda M, Uematsu M, Horio T, Fukuyama N, Hino J, Harada-Shiba M, Okumura H, Tabata Y, Mochizuki N, Chiba Y, Nishioka K, Miyatake K, Asahara T, Hara H, Mori H (2003) Hybrid cellvgene therapy for pulmonary hypertension based on phagocytosing action of endothelial progenitor cells. Circulation 108:889–895

    Article  CAS  PubMed  Google Scholar 

  58. Zhao YD, Courtman DW, Deng Y, Kugathasan L, Zhang Q, Stewart DJ (2005) Rescue of monocrotaline-induced pulmonary arterial hypertension using bone marrow-derived endothelium-like progenitor cells: efficacy of combined cell and eNOS gene therapy in established disease. Circ Res 96:442–450

    Article  CAS  PubMed  Google Scholar 

  59. Bastarache JA, Blackwell TS (2009) Development of animal models for the acute respiratory distress syndrome. Dis Model Mech 2:218–223

    Article  CAS  PubMed  Google Scholar 

  60. Ruscher K, Freyer D, Karsch M, Isaev N, Megow D, Sawitzki B, Priller J, Dirnagl U, Meisel A (2002) Erythropoietin is a paracrine mediator of ischemic tolerance in the brain: evidence from an in vitro model. J Neurosci 22:10291–10301

    CAS  PubMed  Google Scholar 

  61. Sigounas G, Salleng KJ, Mehlhop PD, Sigounas DG (2008) Erythropoietin ameliorates chemotherapy-induced fibrosis of the lungs in a preclinical murine model. Int J Cancer 122:2851–2857

    Article  CAS  PubMed  Google Scholar 

  62. Kamochi M, Kamochi F, Kim YB, Sawh S, Sanders JM, Sarembock I, Green S, Young JS, Ley K, Fu SM, Rose CE Jr (1999) P-selectin and ICAM-1 mediate endotoxin-induced neutrophil recruitment and injury to the lung and liver. Am J Physiol 277:L310–319

    CAS  PubMed  Google Scholar 

  63. Vachharajani V, Vital S, Russell J (2010) Modulation of circulating cell-endothelial cell interaction by erythropoietin in lean and obese mice with cecal ligation and puncture. Pathophysiology 17:9–18

    Article  CAS  PubMed  Google Scholar 

  64. Liu X, Xie W, Liu P, Duan M, Jia Z, Li W, Xu J (2006) Mechanism of the cardioprotection of rhEPO pretreatment on suppressing the inflammatory response in ischemia-reperfusion. Life Sci 78:2255–2264

    Article  CAS  PubMed  Google Scholar 

  65. Remick DG, Bolgos GR, Siddiqui J, Shin J, Nemzek JA (2002) Six at six: interleukin-6 measured 6 h after the initiation of sepsis predicts mortality over 3 days. Shock 17:463–467

    Article  PubMed  Google Scholar 

  66. Takala A, Jousela I, Takkunen O, Kautiainen H, Jansson SE, Orpana A, Karonen SL, Repo H (2002) A prospective study of inflammation markers in patients at risk of indirect acute lung injury. Shock 17:252–257

    Article  PubMed  Google Scholar 

  67. Yano M, Omoto Y, Yamakawa Y, Nakashima Y, Kiriyama M, Saito Y, Fujii Y (2001) Increased matrix metalloproteinase 9 activity and mRNA expression in lung ischemia-reperfusion injury. J Heart Lung Transplant 20:679–686

    Article  CAS  PubMed  Google Scholar 

  68. Abraham E (2003) Nuclear factor-κB and its role in sepsis-associated organ failure. J Infect Dis 187:S362–369

    Google Scholar 

  69. Liu S, Feng G, Wang GL, Liu GJ (2008) p38 MAPK inhibition attenuates lipopolysaccharide induced acute lung injury involvement of NF-kappaB pathway. Eur J Pharmacol 584:159–165

    Article  CAS  PubMed  Google Scholar 

  70. Wu WT, Hu TM, Lin NT, Subeq YM, Lee RP, Hsu BG (2010) Low-dose erythropoietin aggravates endotoxin-induced organ damage in conscious rats. Cytokine 49:155–162

    Article  CAS  PubMed  Google Scholar 

  71. Hojman P, Taudorf S, Lundby C, Pedersen BK (2009) Erythropoietin augments the cytokine response to acute endotoxin-induced inflammation in humans. Cytokine 45:154–157

    Article  CAS  PubMed  Google Scholar 

  72. Beckman JS, Beckman TW, Chen J, Marshall PA, Freeman BA (1990) Apparent hydroxyl radical production by peroxynitrite: implications for endothelial injury from nitric oxide and superoxide. Proc Natl Acad Sci USA 87:1620–1624

    Article  CAS  PubMed  Google Scholar 

  73. Lang JD, McArdle PJ, O'Reilly PJ, Matalon S (2002) Oxidant-antioxidant balance in acute lung injury. Chest 122:314S–320S

    Article  CAS  PubMed  Google Scholar 

  74. Santhanam AV, Smith LA, Nath KA, Katusic ZS (2006) In vivo stimulatory effect of erythropoietin on endothelial nitric oxide synthase in cerebral arteries. Am J Physiol Heart Circ Physiol 291:H781–6

    Article  CAS  PubMed  Google Scholar 

  75. Vollmar B, Eipel C, Menger MD (2010) Therapeutic effects of erythropoietin in murine models of endotoxin shock. Crit Care Med 38:340–1

    Article  PubMed  Google Scholar 

  76. Chakraborty M, Ghosal J, Biswas T, Datta AG (1988) Effect of erythropoietin on membrane lipid peroxidation, superoxide dismutase, catalase, and glutathione peroxidase of rat Rbc. Biochem Med Metab Biol 40:8–18

    Article  CAS  PubMed  Google Scholar 

  77. Genc S, Akhisaroglu M, Kuralay F, Genc K (2002) Erythropoietin restores glutathione peroxidase activity in 1-methyl-4-phenyl-1,2,5,6-tetrahydropyridine-induced neurotoxicity in C57BL mice and stimulates murine astroglial glutathione peroxidase production in vitro. Neurosci Lett 321:73–76

    Article  CAS  PubMed  Google Scholar 

  78. Bany-Mohammed FM, Slivka S, Hallman M (1996) Recombinant human erythropoietin: possible role as an antioxidant in premature rabbits. Pediatr Res 40:381–387

    Article  CAS  PubMed  Google Scholar 

  79. Kaptanoglu E, Solaroglu I, Okutan O, Surucu HS, Akbiyik F, Beskonakli E (2004) Erythropoietin exerts neuroprotection after acute spinal cord injury in rats: effect on lipid peroxidation and early ultrastructural findings. Neurosurg Rev 27:113–120

    Article  PubMed  Google Scholar 

  80. Akimoto T, Kusano E, Muto S, Fujita N, Okada K, Saito T, Komatsu N, Ono S, Ebata S, Ando Y, Homma S, Asano Y (1999) The effect of erythropoietin on interleukin-1beta mediated increase in nitric oxide synthesis in vascular smooth muscle cells. J Hypertens 17:1249–1256

    Article  CAS  PubMed  Google Scholar 

  81. Corwin HL, Gettinger A, Fabian TC, May A, Pearl RG, Heard S, An R, Bowers PJ, Burton P, Klausner MA, Corwin MJ, EPO Critical Care Trials Group (2007) Efficacy and safety of epoetin alfa in critically ill patients. N Engl J Med 357:965–976

    Article  CAS  PubMed  Google Scholar 

  82. Silver M, Corwin MJ, Bazan A, Gettinger A, Enny C, Corwin HL (2006) Efficacy of recombinant human erythropoietin in critically ill patients admitted to a long-term acute care facility: a randomized, double-blind, placebo-controlled trial. Crit Care Med 34:2310–2316

    Article  CAS  PubMed  Google Scholar 

  83. Kao R, Xenocostas A, Rui T, Yu P, Huang W, Rose J, Martin CM (2007) Erythropoietin improves skeletal muscle microcirculation and tissue bioenergetics in a mouse sepsis model. Crit Care 11:R58

    Article  PubMed  Google Scholar 

  84. Leist M, Ghezzi P, Grasso G, Bianchi R, Villa P, Fratelli M, Savino C, Bianchi M, Nielsen J, Gerwien J, Kallunki P, Larsen AK, Helboe L, Christensen S, Pedersen LO, Nielsen M, Torup L, Sager T, Sfacteria A, Erbayraktar S, Erbayraktar Z, Gokmen N, Yilmaz O, Cerami-Hand C, Xie QW, Coleman T, Cerami A, Brines M (2004) Derivatives of erythropoietin that are tissue protective but not erythropoietic. Science 305:239–242

    Article  CAS  PubMed  Google Scholar 

  85. Villa P, Bigini P, Mennini T, Agnello D, Laragione T, Cagnotto A, Viviani B, Marinovich M, Cerami A, Coleman TR, Brines M, Ghezzi P (2003) Erythropoietin selectively attenuates cytokine production and inflammation in cerebral ischemia by targeting neuronal apoptosis. J Exp Med 198:971–975

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Anatomy, Medical School, University of Athens, P.O. Box 11527, 75 M.Asias, Goudi, Athens, Greece

    Sotirios Kakavas, Theano Demestiha, Panagiotis Vasileiou & Theodoros Xanthos

Authors
  1. Sotirios Kakavas
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Theano Demestiha
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Panagiotis Vasileiou
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Theodoros Xanthos
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Theodoros Xanthos.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Kakavas, S., Demestiha, T., Vasileiou, P. et al. Erythropoetin as a novel agent with pleiotropic effects against acute lung injury. Eur J Clin Pharmacol 67, 1–9 (2011). https://doi.org/10.1007/s00228-010-0938-7

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00228-010-0938-7

Keywords

Search

Navigation